Skip to content
Loading…
Braveheart Bio Inc., a clinical-stage biopharmaceutical company backed by a16z, is seeking to raise as much as $318.8 million in an initial public offering, adding to a growing pipeline of listings in the sector.
To respect copyright, we link to the source rather than republishing the full text. Read the complete article on Bloomberg.